An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 May 2018
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Registrational
- Sponsors Boehringer Ingelheim Pharmaceuticals; Unilfarma
- 24 May 2018 Planned End Date changed from 30 Jun 2018 to 28 Dec 2018.
- 24 May 2018 Planned primary completion date changed from 31 Mar 2018 to 28 Nov 2018.
- 28 Feb 2018 Planned End Date changed from 31 Mar 2018 to 30 Jun 2018.